Arcangelo Liso Selected Research

Nucleophosmin

1/2011	Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?
11/2010	CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice.
8/2008	A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1).
5/2008	Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice.
3/2008	Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.
7/2007	Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants.
4/2007	Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.
12/2006	Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification.
9/2006	Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia.
6/2006	Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Arcangelo Liso Research Topics

Disease

18	Neoplasms (Cancer) 06/2022 - 01/2004
12	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2011 - 01/2003
6	Leukemia 11/2010 - 01/2003
4	Inflammation (Inflammations) 06/2022 - 02/2018
3	Hyperthermia 06/2020 - 09/2017
3	Residual Neoplasm 05/2008 - 10/2004
2	Glioblastoma (Glioblastoma Multiforme) 07/2022 - 06/2022
2	Primary Myelofibrosis (Myelosclerosis) 12/2021 - 03/2004
2	Myeloid Leukemia (Leukemia, Myelocytic) 11/2012 - 10/2004
2	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 04/2007 - 02/2004
2	Hematologic Neoplasms (Hematological Malignancy) 04/2007 - 04/2005
2	Lymphoma (Lymphomas) 04/2007 - 01/2005
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2004 - 01/2003
1	Carcinoma (Carcinomatosis) 06/2022
1	Fibrosis (Cirrhosis) 04/2022
1	Immune System Diseases (Immune Disorders) 04/2022
1	Breast Neoplasms (Breast Cancer) 01/2022
1	Flushing 10/2021
1	Autoimmune Diseases (Autoimmune Disease) 10/2018
1	Fever (Fevers) 10/2018
1	Necrosis 09/2017
1	Rheumatoid Arthritis 01/2017
1	Infertility (Sterility) 01/2017
1	Hepatocellular Carcinoma (Hepatoma) 03/2013
1	Telangiectasis (Telangiectasia) 02/2011
1	Chromosome Aberrations (Chromosome Abnormalities) 01/2011
1	Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal) 11/2010
1	Lymphoid Leukemia 04/2005
1	B-Cell Lymphoma (Lymphoma, B Cell) 12/2004
1	Cytopenia 03/2004
1	Hairy Cell Leukemia 01/2004
1	Hereditary Hemorrhagic Telangiectasia 01/2003
1	Pneumonia (Pneumonitis) 01/2003
1	Mycosis Fungoides 01/2003
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 11/2002

Drug/Important Bio-Agent (IBA)

11	NucleophosminIBA 01/2011 - 01/2005
10	Proteins (Proteins, Gene)FDA Link 06/2022 - 12/2004
8	Insulin-Like Growth Factor Binding Protein 6IBA 06/2022 - 01/2017
7	Biological ProductsIBA 10/2018 - 01/2004
3	Lactic Acid (Lactate)FDA LinkGeneric 07/2022 - 01/2022
3	Insulin-Like Growth Factor Binding ProteinsIBA 04/2022 - 10/2018
3	Conditioned Culture MediaIBA 06/2020 - 09/2017
2	Insulin-Like PeptidesIBA 02/2018 - 01/2017
2	AntibodiesIBA 01/2017 - 04/2007
2	AnthracyclinesIBA 04/2005 - 01/2003
2	Monoclonal AntibodiesIBA 04/2005 - 10/2004
2	Alemtuzumab (Campath)FDA Link 01/2004 - 01/2003
1	PlatinumIBA 06/2022
1	Cytokine Receptors (Cytokine Receptor)IBA 12/2021
1	Toll-Like Receptor 4IBA 12/2021
1	WastewaterIBA 10/2021
1	Messenger RNA (mRNA)IBA 06/2020
1	Nitric Oxide Synthase (NO Synthase)IBA 03/2018
1	NitrogenIBA 03/2018
1	CalciumIBA 03/2018
1	Oxygen (Dioxygen)IBA 03/2018
1	AntioxidantsIBA 03/2018
1	Insulin-Like Growth Factor II (Somatomedin A)IBA 01/2017
1	Complement System Proteins (Complement)IBA 01/2017
1	Peptides (Polypeptides)IBA 01/2017
1	Chemotactic FactorsIBA 01/2017
1	AntigensIBA 01/2017
1	Cancer VaccinesIBA 01/2017
1	Sorafenib (BAY 43-9006)FDA Link 03/2013
1	Bevacizumab (Avastin)FDA Link 02/2011
1	CytokinesIBA 11/2010
1	Nuclear Proteins (Protein, Nuclear)IBA 05/2008
1	NucleotidesIBA 03/2008
1	MicroRNAs (MicroRNA)IBA 03/2008
1	Nuclear Export Signals (Nuclear Export Signal)IBA 07/2007
1	Anaplastic Lymphoma KinaseIBA 04/2007
1	ParaffinIBA 09/2006
1	EpitopesIBA 12/2005
1	polyacrylamideIBA 04/2005
1	Annexin A6IBA 04/2005
1	Troponin IIBA 04/2005
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2005
1	DNA (Deoxyribonucleic Acid)IBA 01/2005
1	HSP70 Heat-Shock Proteins (Heat-Shock Protein 70)IBA 01/2005
1	PAX5 Transcription FactorIBA 10/2004
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 10/2004
1	Adrenal Cortex Hormones (Corticosteroids)IBA 03/2004
1	adhesion receptorIBA 01/2004
1	ChemokinesIBA 01/2004
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2003
1	Pharmaceutical PreparationsIBA 11/2002

Therapy/Procedure

8	Therapeutics 06/2022 - 11/2002
2	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 01/2006 - 02/2004
1	Immunotherapy 04/2022
1	Bathroom Equipment 10/2021
1	Induced Hyperthermia (Thermotherapy) 03/2018
1	Molecular Targeted Therapy 05/2008
1	Transplantation 01/2006
1	Drug Therapy (Chemotherapy) 01/2003
1	Salvage Therapy 01/2003